In acute asthma exacerbations, should intramuscular terbutaline be used instead of intramuscular epinephrine?

Intramuscular Epinephrine and Terbutaline Are Equivalent for Acute Asthma—Neither Should Be First-Line

In acute asthma exacerbations, both intramuscular epinephrine and terbutaline are considered equivalent second-line options when inhaled beta-agonists fail, but neither offers proven advantages over inhaled therapy and both carry cardiovascular risks. The choice between them is clinically irrelevant because inhaled selective beta-2 agonists should always be used first.

Primary Treatment Algorithm

The evidence consistently prioritizes this approach:

1. First-line: Inhaled beta-2 agonists (albuterol/salbutamol 5 mg or terbutaline 10 mg nebulized) 1
2. Add systemic corticosteroids (prednisolone 30-60 mg or IV hydrocortisone 200 mg) 2
3. Add ipratropium bromide (0.5 mg nebulized) for severe exacerbations 1
4. Only if life-threatening features persist: Consider parenteral beta-agonists (IV aminophylline, IV salbutamol/terbutaline, or subcutaneous epinephrine/terbutaline) 2

When Parenteral Therapy Is Considered

Life-threatening features requiring escalation include:

• Peak flow <33% predicted
• Silent chest, cyanosis, or feeble respiratory effort
• Bradycardia, hypotension, exhaustion, confusion, or coma
• Normal or elevated PaCO2 in a breathless patient 2, 3

Epinephrine vs Terbutaline: The Evidence

Guideline Consensus

The 2010 AHA guidelines explicitly state: "There is no evidence that subcutaneous epinephrine or terbutaline has advantages over inhaled β2-agonists" 4. Both are listed as equivalent options when parenteral therapy is deemed necessary.

Dosing (when used):

• Epinephrine: 0.01 mg/kg (max 0.3-0.5 mg) subcutaneously every 20 minutes for 3 doses 1, 4
• Terbutaline: 0.25 mg subcutaneously every 20 minutes for 3 doses (children: 0.01 mg/kg) 1, 4

Comparative Research Findings

The older comparative studies from the 1970s found both agents equally effective for bronchodilation 5, 6, 7, 8:

• Bronchodilation: Equivalent between both drugs, occurring within 5 minutes and lasting 4 hours 7
• Cardiovascular effects: Terbutaline at 0.25 mg had similar side effects to epinephrine 0.25 mg, but terbutaline 0.5 mg caused more pronounced effects 8
• Heart rate: One study found terbutaline caused greater tachycardia (25% increase) than epinephrine at equivalent bronchodilator doses 5, while others found small increases with terbutaline but not epinephrine 7

Critical Safety Concerns

Terbutaline carries significant warnings:

• FDA labeling emphasizes cardiovascular effects including tachycardia, arrhythmias, hypokalemia, and potential myocardial ischemia 9
• Doses >0.25 mg consistently produce tachycardia 5
• Recent pediatric data shows terbutaline use was associated with increased hospital admissions (OR 1.55) and PICU admissions, though this may reflect disease severity 10

Epinephrine concerns:

• Non-selective adrenergic effects cause increased myocardial oxygen demand and potential irritability 4
• However, well-tolerated even in patients >35 years old 4
• IV epinephrine showed 4% incidence of serious side effects in one retrospective study 4

Clinical Reality: Why This Question Misses the Point

The fundamental issue is that you should rarely need to choose between these agents because:

1. Inhaled therapy is superior: Multiple actuations of MDI with spacer (20-40 puffs) or continuous nebulization provides equivalent or better bronchodilation without systemic side effects 1

2. IV beta-agonists are preferred if parenteral therapy is needed: The British Thoracic Society guidelines recommend IV aminophylline (250 mg over 20 minutes) or IV salbutamol/terbutaline (250 µg over 10 minutes) for life-threatening features 2

3. Modern adjuncts are more evidence-based: IV magnesium sulfate (2 g over 20 minutes) has better evidence for reducing admissions in severe exacerbations 4

Practical Recommendation

If you must use IM therapy (e.g., patient cannot cooperate with inhaled therapy, no IV access immediately available):

• Use either epinephrine or terbutaline at the lower dose (epinephrine 0.3 mg or terbutaline 0.25 mg)
• Monitor heart rate and blood pressure closely
• Check potassium levels as both can cause hypokalemia 9
• Transition to inhaled therapy as soon as feasible
• Do not use in patients with significant cardiac disease without careful risk-benefit assessment 9

Common Pitfalls

• Overestimating the need for parenteral therapy: Most patients respond to aggressive inhaled therapy with steroids
• Using higher doses of terbutaline (0.5 mg): This consistently causes more cardiovascular effects without additional benefit 5, 8
• Delaying systemic corticosteroids: These are critical and should be given immediately, not after parenteral bronchodilators fail 2, 1
• Forgetting ipratropium: Adding this to beta-agonists reduces hospitalizations in severe exacerbations 1